Emany Sravan Kumar 4

4 · Kyverna Therapeutics, Inc. · Filed Feb 26, 2026

AI-generated summary of this filing

Updated Feb 26, 2026

Kyverna (KYTX) Director Emany Sravan Kumar Receives Equity Award

What Happened

Emany Sravan Kumar, a director of Kyverna Therapeutics (KYTX), received equity awards on 2026-02-24. The Form 4 reports (1) 11,006 restricted stock units (RSUs) granted at $0 and (2) 42,945 derivative shares (an option or option-like award) granted at $0. Combined, the awards cover 53,951 shares; no cash was paid at grant.

Key Details

Transaction date: 2026-02-24; Form 4 filed: 2026-02-26 (filed within typical two-business-day window).
Prices and values: both grants reported at $0 acquisition price (standard for equity compensation grants); total immediate cash value not reported.
Vesting: the 11,006 RSUs vest 1/3 on each anniversary of the grant (footnote F1). The 42,945 derivative shares vest monthly at 1/36th per month (footnote F2).
Shares owned after transaction: not disclosed in the provided filing excerpt.
Transaction code: A (award/grant). No sale or exercise reported here.

Context

These are compensation awards tied to continued service; they typically vest over time and are not immediately sellable until vested. The derivative award appears to be an option-style grant with monthly vesting over three years. This is a grant (not a market purchase or sale) and should be viewed as compensation rather than an immediate vote of market confidence.

Form 4

Period: 2026-02-24

Director

Transactions

Award
Common Stock
[F1]
2026-02-24+11,006→ 11,006 total
Award
Stock Option (right to buy)
[F2]
2026-02-24+42,945→ 42,945 total
Exercise: $7.95Exp: 2036-02-24→ Common Stock (42,945 underlying)

Footnotes (2)

[F1]Represents a restricted stock unit award of common stock and 1/3rd of the shares underlying the restricted stock unit award shall vest on each one-year anniversary of the date of grant, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
[F2]1/36th of the shares subject to the option shall vest on each monthly anniversary of the date of grant, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Signature

/s/ Marc Grasso, as Attorney-in-Fact|2026-02-26

1 file